Table 1.

Different risk groups of endometrial carcinoma

Risk group	ESMO-ESGO-ESTRO consensus1	GOG-994	PORTEC-15
Low risk	Endometrioid endometrial cancer, grade 1–2, <50% myometrial invasion, lymphovascular space invasion negative	Endometrioid endometrial cancer, no myometrial invasion	Endometrioid endometrial cancer, any age, grade 1–2 <50% myometrial invasion
Low-intermediate risk	Endometrioid endometrial cancer, grade 1–2, ≥50% myometrial invasion, lymphovascular space invasion negative	Endometrioid endometrial cancer, not high-intermediate risk	Endometrioid endometrial cancer, grade 1–2, age <60, ≥50% myometrial invasion
High-intermediate risk	Endometrioid endometrial cancer, grade 3, <50% myometrial invasion, any lymphovascular space invasion	Endometrioid endometrial cancer, ≥50% with two factors: lymphovascular space invasion, grade 3, ≥66% myometrial invasion age or ≥70% with one factor	Endometrioid endometrial cancer, grade 1–2, age ≥60, ≥50% myometrial invasion
	Endometrioid endometrial cancer, grade 1–2, lymphovascular space invasion unequivocally positive, any myometrial invasion	Endometrioid endometrial cancer, any age, with all factors: grade 3, ≥66% myometrial invasion and lymphovascular space invasion	Endometrioid endometrial cancer, grade 3, age ≥60, <50% invasion
High	Endometrioid endometrial cancer, grade 3, ≥50% myometrial invasion, any lymphovascular space invasion	Stage II–III endometrioid endometrial cancer	Endometrioid endometrial cancer, grade 3, ≥50% myometrial invasion
	Stage II–III endometrioid endometrial cancer, no residual disease	Stage I–III non-endometrioid endometrial cancer	Stage II–III endometrioid endometrial cancer
	Non-endometrioid endometrial cancer stage I–III (serous, clear cell, or undifferentiated carcinosarcoma)		Stage I–III non-endometrioid endometrial cancer (serous or clear cell)
Advanced/ metastatic	Stage III with residual disease and stage IVa Stage IVb	Stage IV	Stage IV

ESGO, European Society of Gynecological Oncology; ESMO, European Society for Medical Oncology; ESTRO, European Society; GOG, Gynaecologic Oncology Group; PORTEC, Post Operative Radiation Therapy for Endometrial Carcinoma.